RGCC International

08/04/2026

We’re excited to be featured in Finanz und Wirtschaft’s special issue, “Invest in Health.”

In this interview, our Founder and CEO, Dr. Ioannis Papasotiriou, shares insights on the growing importance of prevention and innovation in healthcare.

📖 Scroll to page 5 to read the full interview (in German):

Welcome to Issuu's blog: home to product news, tips, resources, interviews (and more) related to content marketing and publishing.

01/04/2026

At , we support healthcare professionals in delivering precision at every stage of the patient journey, from early detection to treatment guidance and long-term monitoring.

Empower your clinical decisions with RGCC’s comprehensive portfolio of advanced diagnostic tests.

🧬 Explore our tests: rgcc-international.com/tests

25/03/2026

Early detection can make a critical difference in cancer care.

In this short video, Dr. Ana Paz, a medical practitioner in Lisbon, Portugal, shares her experience using RGCC testing in clinical practice. Working within a multidisciplinary clinic, she explains how circulating tumor cell (CTC) analysis can support cancer screening and patient monitoring.

Dr. Paz also shares a personal story from within her own family, where RGCC testing detected circulating tumor cells before conventional imaging identified a developing tumor. This early insight enabled timely intervention and treatment.

Experiences like this highlight the potential of advanced diagnostic tools to support earlier detection and more informed clinical decision-making.

▶️ Watch the full interview on YouTube: https://www.youtube.com/watch?v=sfTVxKtdoC0

19/03/2026

What is the optimal strategy for adjusting second-line treatment for advanced pancreatic using circulating cells (CTCs)?

Developed through a collaboration between scientists and clinical oncologists, our 2025 study: "Second-line therapy adjustment for advanced pancreatic cancer using circulating tumor cells: Preliminary results," investigates the potential of to guide second-line chemotherapy decisions in advanced pancreatic , offering a personalized approach.

👉 Click here to read all our published studies:

Experts in developing and providing personalised cancer genetic tests for doctors and patients, RGCC is a specialist medical genetics company based in Switzerland, with laboratories worldwide.

16/03/2026

Metastat is an advanced diagnostic test that investigates the proteins and genes associated with the metastatic spread of . By analyzing circulating tumor cells (CTCs) from the patient’s blood sample, the test can help determine whether the cells have a high likelihood of metastasizing or if a secondary cancerous tumor is likely to develop, and where in the body it may occur.

🔗 Learn more: rgcc-international.com/tests/metastat/

12/03/2026

Last month, as part of his official tour of Northern Greece, the Ambassador of Indonesia, H.E. Dr. Bebeb A.K. Nugraha Djundjunan, visited RGCC’s laboratories in Florina.

During his visit, the Ambassador was given a guided tour of RGCC’s state-of-the-art facilities and was introduced to the company’s research activities and innovations in precision .

The visit concluded with a shared expression of intent to strengthen collaboration through the exchange of expertise and resources.

Would you like to stay up to date with our latest news, research, and events?
🔗 Subscribe to our newsletter: rgcc-international.com/join-our-mailing-list/

08/03/2026

On International Women’s Day 2026, we celebrate the women whose expertise, leadership, and dedication drive progress in worldwide.

At Central Europe in Halle (Saale), women represent more than 80% of our team: scientists, team members, and leaders shaping the future of oncology and precision medicine.

Today, we honor the journeys, ambition, and impact of the women advancing research and improving patient care worldwide.

05/03/2026

Every patient journey is unique, and so is the care they deserve.

P.W.’s testimonial reflects our commitment to combining advanced diagnostics with compassionate, patient-centered care, supporting informed treatment decisions at every step.

🌱 Read more patient stories: rgcc-international.com/testimonials/

02/03/2026

March is Colorectal Awareness Month.

According to the World Health Organization (WHO), colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer-related deaths.

Awareness, prevention, and early detection matter. Healthy lifestyle choices, such as staying active, eating more fruits and vegetables, limiting processed meats, and avoiding smoking and excessive alcohol, can help reduce risk.

🎗️ Let’s raise awareness and encourage prevention.

25/02/2026

Our Oncotrace test is a powerful monitoring tool designed to assess cancer progression. Through a simple blood draw, Oncotrace detects and analyzes circulating tumor cells ( ), evaluating their presence, enumeration, and immunophenotype. This information helps determine how advanced the cancer is and the potential for metastatic spread.

🎥 Watch the video to hear what our practitioners say about .

19/02/2026

Have you read the real-world study?
A real-world study shows that circulating tumor cell (CTC) analysis can guide personalized treatment and improve outcomes for women with advanced or recurrent ovarian .

The study, “Tailoring treatment for advanced and/or recurrent using the response of circulating tumor cells to therapy: a retrospective analysis,” found that CTC-guided approaches may extend time on treatment and help predict longer survival.

Using data from ’s Onconomics test, physicians were able to tailor therapies based on CTC counts, biomarker expression, chemosensitivity, and mRNA profiling, reinforcing the value of precision diagnostics in cancer care.

🔍 Read it here: rgcc-international.com/news/ovarian-cancer-care/

16/02/2026

Shining the spotlight on our sister company, Welmedis!

Aiming to transform cancer therapy by developing targeted therapeutics, Welmedis is dedicated to developing novel medications that target the unique characteristics of each patient’s cancer, offering more effective and tailored therapeutic solutions.

Using gene and protein expression data from the target identification pipeline, Welmedis identifies novel targets for small-molecule therapeutics tailored to specific patient populations. Their innovative approach combines cutting-edge diagnostics and drug development to provide the most effective treatments for specific cancer types.

Learn more about Welmedis >

We deliver personalized cancer treatments powered by diagnostic insights. Discover more about our mission and our cutting-edge work.